Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Ann Surg Oncol. 2011 Jul;18(7):1837-44. doi: 10.1245/s10434-010-1468-3. Epub 2010 Dec 14.
Male breast cancer accounts for less than 1% of all breast cancers, yet males have a worse prognosis than females with breast cancer.
Using the 1988-2003 Surveillance, Epidemiology, and End Results Program data, we conducted a retrospective, population-based cohort study to investigate stage-specific differences in breast cancer-specific and all-cause mortality between males and females. We calculated adjusted hazard ratios (aHR) and 95% confidence intervals (CI) using Cox regression models to compare breast cancer-specific and all-cause mortality by stage between males and females, controlling for potential confounding variables.
There were 246,059 patients with a first, single, primary breast cancer [1,541 (0.6%) male; 244,518 (99.4%) female]. Compared with females, males were more likely to be older, Black, married, diagnosed at more advanced stages, and treated with mastectomy (each P < 0.001). Males also were more likely to have lower grade and estrogen/progesterone receptor-positive tumors (each P < 0.001). After controlling for confounders, males were more likely to die from their breast cancer when compared with females, only if diagnosed with stage I disease (aHR 1.72, CI 1.15-2.61). For all-cause mortality, males were more likely than females to die at each stage of disease except stage IV.
Although all-cause mortality was higher for men than women at all stages of nonmetastatic breast cancer, higher male breast cancer-specific mortality was attributed to poorer survival in stage I disease. However, this statistical difference is unlikely to be clinically relevant and attributable to in-stage migration.
男性乳腺癌占所有乳腺癌的比例不到 1%,但男性的预后比女性乳腺癌患者差。
利用 1988-2003 年监测、流行病学和最终结果计划的数据,我们进行了一项回顾性、基于人群的队列研究,以调查男性和女性乳腺癌特异性和全因死亡率在特定阶段的差异。我们使用 Cox 回归模型计算调整后的危险比(aHR)和 95%置信区间(CI),以比较男性和女性乳腺癌特异性和全因死亡率的阶段差异,同时控制潜在的混杂变量。
共有 246059 名首次患有单一原发性乳腺癌的患者[1541 名(0.6%)为男性;244518 名(99.4%)为女性]。与女性相比,男性更可能年龄较大、为黑人、已婚、诊断时处于更晚期、接受乳房切除术(均 P<0.001)。男性也更可能患有较低分级和雌激素/孕激素受体阳性的肿瘤(均 P<0.001)。在控制混杂因素后,与女性相比,只有在诊断为 I 期疾病时,男性死于乳腺癌的可能性更大(aHR 1.72,CI 1.15-2.61)。对于全因死亡率,除了 IV 期,男性死于疾病各个阶段的可能性都大于女性。
尽管在非转移性乳腺癌的所有阶段,男性的全因死亡率都高于女性,但男性乳腺癌特异性死亡率较高归因于 I 期疾病的生存率较低。然而,这种统计学差异不太可能具有临床意义,并且归因于同阶段的迁移。